Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of remdesivir 5-day or 10-day regimens versus standard of care in hospitalized patients with moderate COVID-19
NL-OMON49717Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of remdesivir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Clinical status on Day 11. Started Mar 2020; status: recruiting.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49717.